How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.

Name

Adenosine A2A Receptor: A Prognosis Marker For Lung Cancer

Organization name

National Jewish Health

Profile

Summary

The role of angiogenesis in tumor survival and metastasis is now well recognized.  Hypoxia-inducible transcription factors HIF-1alpha and HIF-2alpha are both known to induce angiogenesis by up regulating a common set of cytokines, including VEGF, but only the activation of HIF-2alpha has been associated with poor prognosis in lung cancer. However, since HIF-2alpha is highly labile, it is a poor candidate for a biomarker.

Scientists at National Jewish Health have discovered that the receptor Adenosine A2A (ADORA2A) is expressed only in response to HIF-2alpha activation and more importantly that the expression of ADORA2A is increased in later stage lung tumors. 

This receptor could therefore be used as a prognosis marker for lung cancer as well as a potential new target for an anti-angiogenic approach to treating lung cancer.

Potential Applications

  • A biomarker for HIF-2alpha activation and therefore for poor prognosis in lung cancer.
  • A target for anti-angiogenic therapy in lung cancer

Advantages of Invention

Since HIF-2alpha is too labile to be used as a marker, ADORA2A instead can be used as readout of HIF-2alpha activation and can be easily measured at the RNA level in biopsy samples.  

State of Development

  • Our scientists have found that Hypoxia increases ADORA2A in vitroHIF-2alpha and not HIF-1alpha regulates ADORA2A expression
  • Over expression of ADORA2A or its activation through agonists leads to an increase in endothelial cell proliferation, migration, and branching ADORA2A expression increases in later stage tumor samples collected from lung cancer patients

Publication

Ahmad et.al. Proc Natl Acad Sci U S A. 2009 Jun 30;106(26):10684-9. Epub 2009 Jun 17.  

Patent Status

U.S. patent application #20090155796. International patent publication #WO2009/065044.

Inventors

Aftab Ahmad, PhD and Carl White, MD

Licensing Status

Available for licensing.

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.

 
 

latest entries